Literature DB >> 3355772

The value of high dose tamoxifen in postmenopausal breast cancer patients progressing on standard doses: a pilot study.

S M Watkins1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3355772      PMCID： PMC2246518          DOI： 10.1038/bjc.1988.72

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


× No keyword cloud information.
  8 in total

1.  Anti-oestrogen therapy of advanced mammary carcinoma.

Authors:  H Westerberg; B Nordenskjöld; A de Schryver; G Notter
Journal:  Acta Radiol Ther Phys Biol       Date:  1976-12

2.  Trial of tamoxifen at a dose of 40 mg daily after disease progression during tamoxifen therapy at a dose of 20 mg daily.

Authors:  J F Stewart; M J Minton; R D Rubens
Journal:  Cancer Treat Rep       Date:  1982-06

3.  Assessment of response to therapy in advanced breast cancer. A project of the programme on clinical oncology of the International Union against Cancer, Geneva, Switzerland.

Authors:  J L Hayward; R D Rubens; P P Carbone; J C Heuson; S Kumaoka; A Segaloff
Journal:  Eur J Cancer       Date:  1978-11       Impact factor: 9.162

4.  Differential sensitivity of human breast cancer cell lines to the growth-inhibitory effects of tamoxifen.

Authors:  R R Reddel; L C Murphy; R E Hall; R L Sutherland
Journal:  Cancer Res       Date:  1985-04       Impact factor: 12.701

5.  Tamoxifen-induced remission in breast cancer by escalating the dose to 40 mg daily after progression on 20 mg daily: a case report and review of the literature.

Authors:  A Manni; B M Arafah
Journal:  Cancer       Date:  1981-08-15       Impact factor: 6.860

6.  Triphenylethylenes: a new class of protein kinase C inhibitors.

Authors:  C A O'Brian; R M Liskamp; D H Solomon; I B Weinstein
Journal:  J Natl Cancer Inst       Date:  1986-06       Impact factor: 13.506

7.  A comparison of two doses of tamoxifen (Nolvadex) in postmenopausal women with advanced breast cancer: 10 mg bd versus 20 mg bd.

Authors:  D G Bratherton; C H Brown; R Buchanan; V Hall; E M Kingsley Pillers; T K Wheeler; C J Williams
Journal:  Br J Cancer       Date:  1984-08       Impact factor: 7.640

8.  The clinical course of bone metastases from breast cancer.

Authors:  R E Coleman; R D Rubens
Journal:  Br J Cancer       Date:  1987-01       Impact factor: 7.640
  8 in total
  6 in total

Review 1.  Clinical pharmacokinetics of endocrine agents used in advanced breast cancer.

Authors:  P E Lønning; E A Lien; S Lundgren; S Kvinnsland
Journal:  Clin Pharmacokinet       Date:  1992-05       Impact factor: 6.447

Review 2.  Tamoxifen. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use.

Authors:  M M Buckley; K L Goa
Journal:  Drugs       Date:  1989-04       Impact factor: 9.546

Review 3.  Genotype-guided tamoxifen therapy: time to pause for reflection?

Authors:  Timothy L Lash; Ernst A Lien; Henrik Toft Sørensen; Stephen Hamilton-Dutoit
Journal:  Lancet Oncol       Date:  2009-08       Impact factor: 41.316

4.  Tamoxifen metabolism: pharmacokinetic and in vitro study.

Authors:  M C Etienne; G Milano; J L Fischel; M Frenay; E François; J L Formento; J Gioanni; M Namer
Journal:  Br J Cancer       Date:  1989-07       Impact factor: 7.640

5.  In vitro sensitivity test of breast cancer cells to hormonal agents in a radionucleotide-incorporation assay.

Authors:  T Watanabe; J Z Wu; K Morikawa; M Fuchigami; M Kuranami; I Adachi; K Yamaguchi; K Abe
Journal:  Jpn J Cancer Res       Date:  1990-05

6.  High-dose tamoxifen in high-hormone-receptor-expressing advanced breast cancer patients: a phase II pilot study.

Authors:  Yanhong Su; Yarui Zhang; Xin Hua; Jiajia Huang; Xiwen Bi; Wen Xia; Xinyue Wang; Zhangzan Huang; Chenge Song; Yongyi Zhong; Yanxia Shi; Shusen Wang; Wei Fan; Zhongyu Yuan
Journal:  Ther Adv Med Oncol       Date:  2021-02-26       Impact factor: 8.168
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.